<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234558</url>
  </required_header>
  <id_info>
    <org_study_id>GLYX13-C201</org_study_id>
    <nct_id>NCT01234558</nct_id>
  </id_info>
  <brief_title>Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression</brief_title>
  <official_title>Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naurex, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Naurex, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether GLYX-13 reduces depression score in
      patients with treatment-resistant depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in depression score</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BPRS+</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLYX-13, 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLYX-13, 5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLYX-13, 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLYX-13</intervention_name>
    <description>single IV dose</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_label>GLYX-13, 1 mg/kg</arm_group_label>
    <arm_group_label>GLYX-13, 5 mg/kg</arm_group_label>
    <arm_group_label>GLYX-13, 10 mg/kg</arm_group_label>
    <other_name>ThrProProThr</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of major depressive disorder consistent with DSM-IV-TR

          -  current episode greater than 8 weeks in duration

          -  Hamilton Depression score &gt;/- 21

          -  less than 25% reduction in depression during current episode assessed by ATRQ

        Exclusion Criteria:

          -  Axis diagnosis of other psychiatric disorders

          -  Experiencing hallucinations, delusions, other psychotic symptomatology

          -  ECT during current episode
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M Burch, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Naurex, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vishaal Mehra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Artemis Clinical Research, San Diego CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raymond Manning, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CNRI-LA, Pico Rivera CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Gross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lehigh Center for Clinical Research, Allentown PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Surinder Randhawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lynn Health Sciences Institute, Oklahoma City OK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Greuner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRI-WW, Philadelphia PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Krefetz, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRI-WW Lordes Hospital, Willingboro NJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benji Kurian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U Texas SW Medical Center, Dallas TX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Lesem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Claghorn-Lesem Research Clinic, Houston TX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Macaluso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center, Univ Kansas, Wichita KS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Murray, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinilabs, New York, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mulitple</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>NMDA antagonist</keyword>
  <keyword>treatment resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 9, 2014</submitted>
    <returned>October 11, 2014</returned>
    <submitted>July 17, 2015</submitted>
    <returned>August 11, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

